Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of N-Methyl Pyrrolidine (Nmp). The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Methyl Pyrrolidine (Nmp) SCHEMBL3633193 | 1.00 | — | — | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL29003481 | 1.00 | HTT (0.37) | — | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL28644118 | 0.96 | — | — | |
| N-Methylpiperidine SCHEMBL571891 | 0.96 | — | — | |
| N-Methylpiperidine SCHEMBL3634083 | 0.96 | — | — | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL3628998 | 0.95 | TDP1 (0.35) | — | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL37881 | 0.95 | — | — | |
| SCHEMBL13864423 | 0.95 | TDP1 (0.35) | — | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL4645 | 0.95 | — | — | |
| N-Methylpiperidine SCHEMBL28226735 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 725 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702151-A1 | MANUFACTURING AND USE OF RECOMBINANT SELF-COMPLEMENTARY AAV VECTORS | Logicbio Therapeutics, Inc. (US) | 2026-03-04 | — | — | EP | claimed |
| EP-4663204-A1 | COMPOUNDS USEFUL FOR THE MODULATION OF THE ACTIVITY OF STING | Sulis Therapeutics ApS (DK) | 2025-12-17 | — | — | EP | claimed |
| EP-4663632-A1 | COMPOUNDS USEFUL FOR THE MODULATION OF THE ACTIVITY OF STING | Sulis Therapeutics ApS (DK) | 2025-12-17 | — | — | EP | claimed |
| US-20250235554-A1 | METHODS FOR IMPROVING ADENO-ASSOCIATED VIRUS (AAV) DELIVERY | NOVARTIS AG (CH) | 2025-07-24 | — | — | US | claimed |
| WO-2025129085-A1 | USE OF THERMAL BIOSWITCHES IN AAV-BASED GENE THERAPY | PORT THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| CN-113383408-B | Treatment liquid for semiconductor wafer containing onium salt | 株式会社德山 | 2025-04-08 | — | — | CN | claimed |
| CN-119242711-A | Treatment of Amyotrophic Lateral Sclerosis (ALS) | 沃雅戈治疗公司 | 2025-01-03 | — | — | CN | claimed |
| WO-2024223931-A1 | MANUFACTURING AND USE OF RECOMBINANT SELF-COMPLEMENTARY AAV VECTORS | AstraZeneca Ireland Limited (IE) | 2024-10-31 | — | — | WO | claimed |
| WO-2024226065-A1 | MANUFACTURING AND USE OF RECOMBINANT SELF-COMPLEMENTARY AAV VECTORS | LOGICBIO THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | claimed |
| WO-2024220537-A2 | TISSUE-DIRECTED ANTIBODIES AND METHODS OF USING THE SAME | ZAG Bio, Inc. (US) | 2024-10-24 | — | — | WO | claimed |
| WO-2019002407-A1 | PROCESS FOR THE PREPARATION OF TIPIRACIL HYDROCHLORIDE | AMNEAL PHARMACEUTICALS COMPANY GMBH (CH) | 2019-01-03 | — | — | WO | claimed |
| EP-2220041-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2010-08-25 | — | — | EP | claimed |
| WO-2009055516-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-30 | — | — | WO | claimed |
| EP-0391646-B1 | A process for the preparation of a poly(paraphenylene terephthalamide) fibrous gel composition and a process to produce poly (Paraphenylene terephthalamide) paper from the composition | DU PONT (US) | 1994-06-15 | — | — | EP | claimed |
| US-5021123-A | Process for producing paper from a poly(paraphenylene terephthalamide) fibrous gel | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-06-04 | — | — | US | claimed |
| EP-0391646-A1 | A process for the preparation of a poly(paraphenylene terephthalamide) fibrous gel composition and a process to produce poly (Paraphenylene terephthalamide) paper from the composition | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-10-10 | — | — | EP | claimed |
| US-4959453-A | Process for the preparation of a poly(paraphenylene terephthalamide)fibrous gel composition and a process to produce poly(paraphenylene terephthalamide) paper from the composition | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-09-25 | — | — | US | claimed |
| US-4871871-A | DECOMPOSING AROMATIC BISDIALKYL UREA WITH TERTIARY AMINE SALT PROMOTER IN SOLVENT | ARCO CHEMICAL TECHNOLOGY, INC. (US) | 1989-10-03 | — | — | US | claimed |
| EP-0069385-B1 | USE OF EUCALYPTOL FOR ENHANCING SKIN PERMEATION OF BIOAFFECTING AGENTS | MERCK & CO. INC. (US) | 1987-10-14 | — | — | EP | claimed |
| EP-0036138-B1 | COMPOSITION OF MATTER FOR TOPICAL APPLICATION COMPRISING A BIO-AFFECTING AGENT AND N,N-DIETHYL-M-TOLUAMIDE | MERCK & CO. INC. (US) | 1985-08-28 | — | — | EP | claimed |